Liu, Xuejun
Jiang, Jenny
Li, Danshi
Horrow, Jay
Tamada, Hiroshi
Kahl, Anja
Hariharan, Vignesh
Avinav, Ankur
Li, Xiaoyan
Funding for this research was provided by:
Bristol Myers Squibb and Janssen Global Services, LLC.
Article History
Received: 20 June 2023
Accepted: 8 September 2023
First Online: 4 October 2023
Declarations
:
: Xuejun Liu was an employee of Bristol Myers Squibb at the time of the study and is a current PhD candidate of the University of North Carolina at Chapel Hill, School of Public Health. Jenny Jiang, Danshi Li, Jay Horrow, Anja Kahl, and Xiaoyan Li are current employees of Bristol Myers Squibb. Hiroshi Tamada was an employee of Bristol Myers Squibb at the time of the study and is currently employed as the founder of Nassau Biopharma Consulting. Vignesh Hariharan was an employee of Mu Sigma Inc. at the time of the study and is a current employee of Accenture. Ankur Avinav was an employee of Mu Sigma Inc. at the time of the study and is a current employee of Indium Software.
: This article had been approved by the Independent Scientific Advisory Committee (ISAC), with the reference number ISAC19_240R. Although this study does not involve primary data collection from human participants, it was performed in accordance with the ethical principles set forth in the Helsinki Declaration of 1964 and its later amendments. Given that this study was based on retrospective analyses of secondary databases without enrollment of patients, all data were anonymized and de-identified prior to analysis.